Thursday, April 2, 2020
Breaking Medical Device Industry News
Home Apollo Endosurgery

Apollo Endosurgery

US Labeling Update on the ORBERA® Intragastric Balloon System

The labeling updates improve patient safety by providing further definition and guidance on the appropriate use of the ORBERA® Intragastric Balloon System and patient selection.

Publication of Outcomes of Endoscopic Sleeve Gastroplasty (ESG) in 1,000 Consecutive Patients

2/19/19: ESG is an endoscopic minimally invasive weight loss procedure based on full-thickness endoscopic suturing using Apollo’s OverStitch™ device. In the ESG procedure, a series of sutures are placed through the gastric wall reducing the stomach volume by 80% creating a restrictive endoscopic sleeve. The result allows a patient to consume less food and remain satiated longer.

Apollo Endosurgery Announces Presentation of Intragastric Balloon Comparison Study at Digestive Disease Week® 2018 titled: “Fluid-Filled Intragastric Balloons are Superior to Gas-Filled Balloon”

6/4/18: “Gastric emptying is the key to how ORBERA helps patients lose weight. When a patient has an ORBERA balloon in their stomach it acts like a valve that slowly allows food they eat to pass through their stomach. Without a balloon a normal meal will typically pass through a patients stomach in 20-30 minutes. Now with an ORBERA balloon in their stomach, we have data that a large portion of that meal would still be in their stomach 2 hours after eating. This delayed emptying helps patients feel full, helps them learn proper portion control and most importantly helps them lose a clinically significant amount of weight,” said Dr. Christopher Gostout, MD, Chief Medical Officer at Apollo.

Apollo Endosurgery Announces Spanish Study of ESG in NASH Patients

5/14/18: The study will involve four National Health System Hospitals, led by Professor José Luis Calleja, MD from Hospital Universitario Puerta de Hierro Majadahonda - Universidad Autónoma de Madrid, as Principal Investigator.

Apollo Endosurgery, Inc. Reports First Quarter 2018 Results

5/4/18: Todd Newton, CEO of Apollo, said, "We are pleased with our first quarter results and 2018 is off to a great start for the Company. Our worldwide Endo-bariatric product sales increased 40% compared to the first quarter of 2017, with OverStitch™ sales more than doubling compared to the same quarter of last year. For Orbera®, the launch of Orbera365™ produced both higher selling prices and increased unit sales in our European markets and in the U.S. Orbera implant volume increased 27% compared to the fourth quarter of 2017 as we rebuild U.S. momentum."

Conclusion of LAP-BAND® Low BMI Post-Approval Study Announced by Apollo Endosurgery

The FDA has approved the termination of the LAP-BAND® Lower Body Mass Index (BMI) Post-approval study (“LBMI...

Apollo Endosurgery Announces Presentation of the Brazilian Intragastric Balloon Consensus Statement at ObesityWeek

According to the company, this presentation reported the results of a consensus meeting held in Sao Paulo, Brazil in June 2016 of 39 endoscopists with up to 17 years of experience providing intragastric balloon therapy to patients.

Apollo Endosurgery Announces CE Mark Approval for the ORBERA365™ Managed Weight Loss System, Expanding the Indwell Period from 6 Months to 12 Months with...

Apollo Endosurgery, Inc. (“Apollo”) (NASDAQ:APEN), a global leader in less invasive medical devices for bariatric and gastrointestinal...